Lisata Therapeutics Inc (LSTA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.99-6.46%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · LSTA
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(20.0) + peer(0.2*0.0) + term(0.0) → 7.0% (capped ±15.0)
Calibrated likelihood the company misses analyst consensus on its next print, read from its own miss history plus its industry base rate. A fundamental tilt, not a price call — and a quiet watch-flag, not an alarm.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Calibrated. Base rate ~24%.
Consecutive quarters it missed, most recent run.
How often this industry misses, baseline.
Industry peers that missed in the recent window.
today
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. The information in
Results of Operations and Financial Condition. The information in
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition. Lisata Therapeutics, Inc. (the “Company”) previously reported in its 10-Q for the period ended March 31, 2025, that it had cash, cash equivalents and marketable securities of approximately $25.8 million, which, based on its existing and planned activities, would support its operations into the third quarter of 2026. The Company now believes that available funds will support current operations into the fourth quarter of 2026.
Results of Operations and Financial Condition. The information in
Results of Operations and Financial Condition. The information in
Results of Operations and Financial Condition. The information in
Results of Operations and Financial Condition. The information in
Results of Operations and Financial Condition. The information in
Results of Operations and Financial Condition. The information in
Results of Operations and Financial Condition. The information in
Results of Operations and Financial Condition. The information in
Results of Operations and Financial Condition. The information in
Results of Operations and Financial Condition. The information in
Results of Operations and Financial Condition. Lisata Therapeutics, Inc. (the “Company”) expects to report that it had cash, cash equivalents and marketable securities of approximately $69.2 million as of December 31, 2022. The estimated cash figure is preliminary and unaudited, represents a management estimate as of the date of this current report on Form 8-K and is subject to completion of the Company’s financial closing procedures. The Company’s independent registered public accounting fir…
Results of Operations and Financial Condition. The information in
Results of Operations and Financial Condition. The information in